Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 7/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | SNCA | P37840 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4347796 | 0.87 | SLC6A4 (0.57) | SLC6A4MTNR1AMTNR1BSNCAHTR1A | |
| SCHEMBL4485828 | 0.83 | TSHR (0.64) | SLC6A4KDM4EALDH1A1LMNAGLA | |
| SCHEMBL4351609 | 0.81 | SLC6A4 (0.50) | SLC6A4NR3C1NR3C2SNCAHTR1A | |
| SCHEMBL21255987 | 0.81 | MTNR1A (0.59) | KDM4EMTNR1AMTNR1BPKMALDH1A1 | |
| SCHEMBL853729 | 0.81 | NPSR1 (0.68) | SLC6A4KDM4EALDH1A1LMNAGLA | |
| SCHEMBL24688676 | 0.80 | SLC6A4 (0.49) | SLC6A4NR3C1NR3C2DRD2DRD4 | |
| SCHEMBL13226846 | 0.80 | SLC6A4 (0.63) | SLC6A4NR3C1NR3C2DRD2DRD4 | |
| SCHEMBL20769666 | 0.80 | MTNR1A (0.60) | SLC6A4KDM4EMTNR1AMTNR1BTSHR | |
| SCHEMBL2686551 | 0.80 | KDM4E (0.77) | KDM4EMTNR1AMTNR1BALDH1A1HPGD | |
| SCHEMBL29444458 | 0.80 | MTNR1A (0.60) | SLC6A4KDM4EMTNR1AMTNR1BPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601751-B2 | Indole acetic acid acyl guanidines as β-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| US-20070049589-A1 | Indole acetic acid acyl guanidines as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-01 | — | — | US | disclosed |
| US-6043257-A | ANTICOAGULANT; PYRIDINE SUBSTITUTED INDAZOLE COMPOUND | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-03-28 | — | — | US | disclosed |
| EP-0960102-A1 | AMIDINOINDOLES, AMIDINOAZOLES, AND ANALOGS THEREOF AS INHIBITORS OF FACTOR Xa AND OF THROMBIN | Du Pont Pharmaceuticals Company (US) | 1999-12-01 | — | — | EP | disclosed |
| US-5886191-A | ANTICOAGULANTS | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-03-23 | — | — | US | disclosed |
| WO-1998001428-A1 | AMIDINOINDOLES, AMIDINOAZOLES, AND ANALOGS THEREOF AS INHIBITORS OF FACTOR Xa AND OF THROMBIN | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049589-A1 | Indole acetic acid acyl guanidines as beta-secretase inhibitors | BACE1, APP, BACE2 | SLC6A4 1375/4885KDM4E 2214/4885MTNR1A 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.